Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents

Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents With Allogeneic Hematopoietic Stem Cell Transplantation

Caspofungin (CAS) is used to prevent and treat invasive fungal infections patients older than 3 months. However, the optimal dosing strategy of CAS is lacking in adolescents from 12 to 17 years old, especially those undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), who are vulnertable to fungal infections. The study aimed to establish a population pharmacokinetic (PPK) model and assess the dosing schemes of CAS in adolescents with allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Inclusion Criteria:

• The adolescents (12 - 17 years) underwent allo-HSCT
• Use caspofungin for the prevention or treatment of fungal infections

Exclusion Criteria:

• Intolerable to caspofungin
• Participate into other clinical studies
• There are conditions that researchers do not consider it appropriate to join the research.